Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an announcement.
China Resources Pharmaceutical Group Ltd. and CR Medical Group have entered into a new Cooperation Framework Agreement for 2026/2028 to continue their collaboration on supply chain management services. This agreement aims to enhance the efficiency and reduce costs of CR Pharmaceutical’s medical supplies supply chain, with CR Medical receiving management service fees. The transactions under this agreement are considered continuing connected transactions and are subject to certain reporting and review requirements under the Listing Rules.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the provision of medical supplies and supply chain management services. The company is involved in improving the efficiency and reducing the costs of supply chain management for medical supplies.
Average Trading Volume: 14,581,121
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.96B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.